type 1 diabetes glp-1 SGLT2i and RA therapy in and reno-vascular outcomes: a real-world study | Diabetologia Scripts for GLP-1, SGLT2 Drugs

The peptide addresses connective tissue conditions (tendonitis and ligament ruptures) by accelerating structural repair at the cellular level

JAMA 2014;311:74-86.ArticlePubMedPMC 862

Seeds is an active researcher in peptide therapy and cellular medicine, publishing widely in peer-reviewed journals

Alhadeff, PhD, senior study author After reviewing this study, Shruti Pandiri, MD, assistant professor of medicine in the Division of Endocrinology with the Center for Weight Loss & Metabolic Health at Hackensack University Medical Center in New Jersey, told MNT the findings of this study have the potential to lead to the development of GLP-1-based obesity drugs with improved tolerability

Acarbose also reduces the clinical expression of DM in patients with IGT in 25% of cases

This may be a sign of orthostatic hypotension , a drop in blood pressure that happens when changing positions